Last reviewed · How we verify

Hemostatic Agent — Competitive Intelligence Brief

Hemostatic Agent (Hemostatic Agent) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Hemostatic agent / Coagulation enhancer. Area: Hematology / Surgery / Oncology.

phase 3 Hemostatic agent / Coagulation enhancer Hematology / Surgery / Oncology Small molecule Live · refreshed every 30 min

Target snapshot

Hemostatic Agent (Hemostatic Agent) — Memorial Sloan Kettering Cancer Center. A hemostatic agent promotes blood clotting and stops bleeding by enhancing coagulation cascade activation or platelet function.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Hemostatic Agent TARGET Hemostatic Agent Memorial Sloan Kettering Cancer Center phase 3 Hemostatic agent / Coagulation enhancer

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Hemostatic agent / Coagulation enhancer class)

  1. Memorial Sloan Kettering Cancer Center · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Hemostatic Agent — Competitive Intelligence Brief. https://druglandscape.com/ci/hemostatic-agent. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators: